Market research
18H.F PreveCeutical Medical Inc
F EUR Healthcare
Latest close
As of 22 Feb 2026
Test a moving-average rule with historical data.
Market facts
- Market cap
- 14M
- P/E ratio
- Not available
- Analyst target
- Not available
- Dividend yield
- Not available
- Beta
- 0.23
Profile
Instrument facts
- Exchange
- F
- Currency
- EUR
- Sector
- Healthcare
- Industry
- Biotechnology
- ISIN
- CA74141E1043
- Market cap
- 14M
- P/E ratio
- Not available
- Analyst target
- Not available
- Dividend yield
- Not available
- Beta
- 0.23
About
About PreveCeutical Medical Inc
PreveCeutical Medical Inc., a health sciences company, engages in the development of options for preventive and curative therapies utilizing organic and nature identical products. Its pipeline products include Cannabinoid Sol-Gel Delivery, a cannabinoid-based nose-to-brain delivery system that provides relief from various indications, including pain, inflammation, seizures, and neurological disorders; Non-Addictive Analgesic for pain management; and BSV Peptide Program that targets cancer progression. The company is headquartered in West Vancouver, Canada.
Research context
PreveCeutical Medical Inc appears in PyInvesting’s Frankfurt Stock catalogue. The price history above describes this recorded instrument; it does not by itself identify a company’s business or establish a continuous investment return.
- Currency
- EUR
- Sector
- Healthcare
- Industry
- Biotechnology
These are the latest stored catalogue classifications, not a historical classification snapshot. An issuer description, classification effective date or currency may be unavailable. Check the issuer’s own disclosures and the observation dates before using these fields for research.
Review backtest assumptions and evidence before treating a chart or stored history as a research result.
Community
Investor discussion
1 comment
Sign in to join the 18H.F discussion.
5 years, 6 months ago
PreveCeutical Medical Inc is currently in a long term downtrend where the price is trading 45.6% below its 200 day moving average.
From a valuation standpoint, the stock is 50.2% more expensive than other stocks from the Healthcare sector with a price to sales ratio of 1973.4.
PreveCeutical Medical Inc's total revenue sank by nan% to $0 since the same quarter in the previous year.
Its net income has increased by 173.8% to $451K since the same quarter in the previous year.
Finally, its free cash flow grew by 1013.7% to $499K since the same quarter in the previous year.
Based on the above factors, PreveCeutical Medical Inc gets an overall score of 2/5.